The Lovesac Company Announces Participation in Upcoming Investor Conference GlobeNewswire October 01, 2025 STAMFORD, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, announced today that the Company is scheduled […]

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire October 01, 2025 CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics(R), Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 204,163 shares

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire October 01, 2025 CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 116,150 restricted stock units (“RSUs”) to four newly hired

Covenant Logistics Group, Inc. Announces Timing of Third Quarter Earnings Release and Conference Call GlobeNewswire October 01, 2025 CHATTANOOGA, Tenn., Oct. 01, 2025 (GLOBE NEWSWIRE) — Covenant Logistics Group, Inc. (NYSE: CVLG) announced its plans to release its third quarter earnings after 4:00 p.m. Eastern time on Wednesday, October 22, 2025. Covenant Logistics Group, Inc.

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference GlobeNewswire October 01, 2025 WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 GlobeNewswire October 01, 2025 Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026 Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) — Bolt Biotherapeutics

QCR Holdings, Inc. to Report Third Quarter 2025 Financial Results GlobeNewswire October 01, 2025 MOLINE, Ill., Oct. 01, 2025 (GLOBE NEWSWIRE) — QCR Holdings, Inc. (NASDAQ: QCRH) (“QCRH” or the “Company”) announced today that its third quarter ended September 30, 2025, financial results will be released after the market closes on Wednesday, October 22, 2025.

Horizon Bancorp, Inc. Announces Conference Call to Review Third Quarter Results on October 23 GlobeNewswire October 01, 2025 MICHIGAN CITY, Ind., Oct. 01, 2025 (GLOBE NEWSWIRE) — (NASDAQ GS: HBNC) — Horizon Bancorp, Inc. (“Horizon” or the “Company”) will host a conference call at 7:30 a.m. CT on Thursday, October 23, 2025 to review its

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron(R) Board of Directors GlobeNewswire October 01, 2025 MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD,

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 GlobeNewswire October 01, 2025 CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and